Prevalence of Sjogren's syndrome in Brazilian patients infected with human T-cell lymphotropic virus

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author VALE, Daniela Assis do
CASSEB, Jorge FMUSP-HC
OLIVEIRA, Augusto Cesar Penalva de
BUSSOLOTI FILHO, Ivo
SOUSA, Suzana Cantanhede Orsini Machado de
ORTEGA, Karem Lopez
dc.date.issued 2017
dc.identifier.citation JOURNAL OF ORAL PATHOLOGY & MEDICINE, v.46, n.7, p.543-548, 2017
dc.identifier.issn 0904-2512
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/22206
dc.description.abstract BackgroundHuman T-lymphotropic virus type I (HTLV-I) is known to be associated with neoplastic and neurodegenerative changes, and it is believed to be associated with various systemic inflammatory diseases, including Sjogren's syndrome (SS). Although HTLV-I infection is endemic in Brazil, there is no information regarding the association between HTLV-I infection and SS in the Brazilian population. The objective of this study was to determine the prevalence of SS in HTLV-I-infected individuals and the prevalence of HTLV-I infection in individuals diagnosed with SS. MethodsSerology for HTLV-I was performed in 50 patients presenting with complaints consistent with SS (the SS group). The HTLV-I group comprised 129 HTLV-I-infected patients who were screened for SS. ResultsNone of the patients in the SS group tested positive for HTLV-I. Of the 129 patients in the HTLV-I group, 46 (35.7%) had xerostomia, 18 (13.95%) had xerophthalmia, eight (6.2%) had hyposalivation, two (1.55%) showed impaired tear secretion, and one (0.77%) was positive for autoantibodies (anti-SSB). In addition, six underwent minor salivary gland biopsy, and the histopathological findings were consistent with SS. Only two (1.55%) met the diagnostic criteria for SS. ConclusionsThe prevalence of SS was found to be three times as high in HTLV-I-infected individuals as it was in those without HTLV-I infection. However, given the small number of HTLV-seropositive patients with SS, it is impossible to state that HTLV acts as an immune-activating pathogen for SS.
dc.language.iso eng
dc.publisher WILEY
dc.relation.ispartof Journal of Oral Pathology & Medicine
dc.rights restrictedAccess
dc.subject HTLV-associated myelopathy; tropical spastic paraparesis; human T-cell lymphotropic virus; Sjogren's syndrome; xerostomia
dc.subject.other salivary-glands; spastic paraparesis; i infection; htlv-i; antibodies; retrovirus; expression; serum
dc.title Prevalence of Sjogren's syndrome in Brazilian patients infected with human T-cell lymphotropic virus
dc.type article
dc.rights.holder Copyright WILEY
dc.description.group LIM/56
dc.identifier.doi 10.1111/jop.12530
dc.identifier.pmid 27925697
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author CASSEB, Jorge:IMT:DVCIENT-83
hcfmusp.author.external · VALE, Daniela Assis do:Univ Sao Paulo, Sch Dent, Dept Stomatol, Special Care Dent Ctr, Sao Paulo, Brazil
· OLIVEIRA, Augusto Cesar Penalva de:Inst Infect Dis Emilio Ribas, Sao Paulo, Brazil
· BUSSOLOTI FILHO, Ivo:Irmandade Santa Casa Misericordia, Dept Otorhinolaryngol, Sao Paulo, Brazil
· SOUSA, Suzana Cantanhede Orsini Machado de:Univ Sao Paulo, Sch Dent, Dept Stomatol, Sao Paulo, Brazil
· ORTEGA, Karem Lopez:Univ Sao Paulo, Sch Dent, Dept Stomatol, Special Care Dent Ctr, Sao Paulo, Brazil
hcfmusp.origem.id 2-s2.0-85007493411
hcfmusp.origem.id WOS:000407039200011
hcfmusp.publisher.city HOBOKEN
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Alamy AH, 2001, ANN NEUROL, V50, P681, DOI 10.1002/ana.1264
· Bangham CRM, 2005, ONCOGENE, V24, P6035, DOI 10.1038/sj.onc.1208970
· Cartier L, 2005, REV MED CHILE, V133, P1183, DOI 10.4067/S0034-98872005001000007
· DALAVANGA YA, 1986, SCAND J RHEUMATOL, P67
· desCarvalho MMN, 2006, REV BRAS REUMATOL, V46, P334
· EGUCHI K, 1992, ANN RHEUM DIS, V51, P769, DOI 10.1136/ard.51.6.769
· Ferraz-Chaoui AK, 2010, RHEUMATOL INT, V30, P775, DOI 10.1007/s00296-009-1066-5
· GESSAIN A, 1985, LANCET, V2, P407
· Lee SJ, 2012, J RHEUMATOL, V39, P809, DOI 10.3899/jrheum.111075
· LEONMONZON M, 1993, MED CLIN-BARCELONA, V100, P121
· Lima CM, 2016, J IMMUNOL RES, DOI 10.1155/2016/8402059
· Liquidato Bianca Maria, 2006, Int. J. Morphol., V24, P489, DOI 10.4067/S0717-95022006000400031
· MARIETTE X, 1995, LANCET, V345, P71, DOI 10.1016/S0140-6736(95)91200-2
· Martins FM, 2010, ORAL DIS, V16, P167, DOI 10.1111/j.1601-0825.2009.01638.x
· Mavragani CP, 2010, AUTOIMMUN REV, V9, pA305, DOI 10.1016/j.autrev.2009.11.004
· Nakamura H, 2000, J LAB CLIN MED, V135, P139, DOI 10.1067/mlc.2000.103429
· Ness Jose, 2006, Am J Geriatr Pharmacother, V4, P42, DOI 10.1016/j.amjopharm.2006.03.008
· POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
· POPOVIC M, 1982, NATURE, V300, P63, DOI 10.1038/300063a0
· Pupo Daniella B., 2002, Rev. Bras. Otorrinolaringol., V68, P219, DOI 10.1590/S0034-72992002000200010
· Rathsam-Pinheiro RH, 2009, REV SOC BRAS MED TRO, V42, P633, DOI 10.1590/S0037-86822009000600004
· SHATTLES WG, 1992, CLIN EXP IMMUNOL, V89, P46
· Shimazaki R, 2002, J NEUROL SCI, V194, P55, DOI 10.1016/S0022-510X(01)00675-X
· TALAL N, 1990, ARTHRITIS RHEUM, V33, P774, DOI 10.1002/art.1780330603
· TERADA K, 1994, LANCET, V344, P1116, DOI 10.1016/S0140-6736(94)90630-0
· Valim V, 2013, REV BRAS REUMATOL, V53, P24
· Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
· Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554
· YAMAGUCHI K, 1994, LANCET, V343, P213, DOI 10.1016/S0140-6736(94)90994-6
dc.description.index MEDLINE
dc.identifier.eissn 1600-0714
hcfmusp.citation.scopus 4
hcfmusp.citation.wos 3
hcfmusp.affiliation.country Brasil


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics